INFLUENCE OF ABCB1 (MDR1) GENE POLYMORPHISMS ON TREATMENT RESPONSE IN OSTEOARTHRITIS: PHARMACOGENOMIC IMPLICATIONS FOR PERSONALIZED THERAPY

Read full text Summarise with VIRAT
Authors: Fattoyorov Feruzbek Dilshodbek ugli, Toʻychiboyev Javohir Ismoiljon ugli, Anorqulov Ozodbek Zoirjon ugli
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Osteoarthritis is the most prevalent chronic joint disorder worldwide and a leading cause of pain, functional limitation, and disability among adults and elderly populations. Traditionally considered a degenerative disease driven primarily by mechanical wear and tear, osteoarthritis is now recognized as a complex, multifactorial condition involving low-grade inflammation, metabolic dysregulation, genetic susceptibility, and alterations in subchondral bone remodeling. The global burden of osteoarthritis continues to rise due to aging populations, increasing obesity rates, and sedentary lifestyles. Despite advances in symptomatic management, many patients experience persistent pain, progressive structural damage, and substantial deterioration in quality of life.

Fields of Study & Subjects

Pharmacogenetics and Drug Metabolism Osteoarthritis Treatment and Mechanisms Drug Transport and Resistance Mechanisms

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
28 March 2026
Language
EN
Document type
Dataset